Clinical trials data
Cognitive tests in cognitive impairment and decline trials: 354 registered studies
Every registered cognitive impairment and decline study on ClinicalTrials.gov that names a cognitive test in an outcome measure: the tests used most, how often as a primary outcome, which tests go together, how large the studies are and when they measure the outcome.
- Registered cognitive impairment and decline studies name a cognitive test in an outcome
- 354
- Led by industry
- 32
The tests cognitive impairment and decline trials use most
Verbal Learning leads: 79 of the 354 studies name it, 22%. Next comes the Trail Making Test (77). As a primary outcome, Verbal Learning leads with 43 studies.
- 1
Verbal Learning79 studies, 43 as a primary outcome
- 2
Trail Making Test77 studies, 33 as a primary outcome
- 3
Verbal Fluency63 studies, 35 as a primary outcome
- 4
Digit Span Test60 studies, 29 as a primary outcome
- 5
Stroop Color-Word Test47 studies, 24 as a primary outcome
- 6
Symbol Coding40 studies, 18 as a primary outcome
- 7
Picture Naming Test23 studies, 15 as a primary outcome
- 8
Category Fluency22 studies, 11 as a primary outcome
- 9
Clock Drawing Task21 studies, 10 as a primary outcome
- 10
N-Back Task16 studies, 10 as a primary outcome
- 11
Complex Figure Copy and Recall14 studies, 7 as a primary outcome
- 12
Continuous Performance Test14 studies, 6 as a primary outcome
- 13
Size Order Memory Test13 studies, 5 as a primary outcome
- 14
Short Story Recall10 studies, 6 as a primary outcome
- 15
Picture Order Memory Test10 studies, 4 as a primary outcome
- 16
Letter-Number Sequencing Task9 studies, 8 as a primary outcome
- 17
Selective Reminding Task9 studies, 6 as a primary outcome
- 18
Dimensional Change Card Sort9 studies, 4 as a primary outcome
- 19
Pattern and Letter Comparison9 studies, 4 as a primary outcome
- 20
Card Sorting Test (Berg)8 studies, 5 as a primary outcome
- 21
Matrix Reasoning8 studies, 4 as a primary outcome
- 22
Paired Associate Learning7 studies, 5 as a primary outcome
- 23
Task Switching Test7 studies, 4 as a primary outcome
- 24
Go/No-Go Task7 studies, 2 as a primary outcome
- 25
Rapid Visual Information Processing6 studies, 5 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
26% of cognitive impairment and decline studies name only instruments outside the library, such as clinician-administered screening scales. They count in every figure on this page and are not listed. The explorer below holds all 82 tests.
Tests used together
- Trail Making Test and Verbal Learning34 studies name both
- Trail Making Test and Verbal Fluency29 studies name both
- Digit Span Test and Verbal Learning27 studies name both
- Stroop Color-Word Test and Trail Making Test26 studies name both
- Digit Span Test and Trail Making Test25 studies name both
- Verbal Fluency and Verbal Learning24 studies name both
- Stroop Color-Word Test and Verbal Learning20 studies name both
- Symbol Coding and Verbal Learning19 studies name both
- Digit Span Test and Verbal Fluency17 studies name both
- Category Fluency and Verbal Learning16 studies name both
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 2 | 1 |
| 2008 | 2 | 2 |
| 2009 | 2 | 2 |
| 2010 | 5 | 4 |
| 2011 | 4 | 1 |
| 2012 | 8 | 7 |
| 2013 | 8 | 7 |
| 2014 | 8 | 5 |
| 2015 | 11 | 7 |
| 2016 | 16 | 10 |
| 2017 | 34 | 18 |
| 2018 | 20 | 14 |
| 2019 | 36 | 22 |
| 2020 | 21 | 14 |
| 2021 | 23 | 16 |
| 2022 | 25 | 15 |
| 2023 | 36 | 22 |
| 2024 | 32 | 24 |
| 2025 | 31 | 19 |
| 2026 | 26 | 17 |
Phases and sponsors
By phase
- Early phase 16 studies, 6 as a primary outcome
- Phase 16 studies, 3 as a primary outcome
- Phase 1/28 studies, 7 as a primary outcome
- Phase 217 studies, 9 as a primary outcome
- Phase 2/33 studies, 2 as a primary outcome
- Phase 36 studies, 5 as a primary outcome
- Phase 419 studies, 12 as a primary outcome
- Not applicable217 studies, 146 as a primary outcome
- Observational72 studies, 40 as a primary outcome
Sponsors and study types
Lead sponsor: industry 32, NIH 0, universities, hospitals and others 322. Interventional 282, observational 72.
Status, results, interventions and countries
Status
- Recruiting57 studies, 38 as a primary outcome
- Not yet recruiting18 studies, 12 as a primary outcome
- Active, not recruiting17 studies, 14 as a primary outcome
- Completed152 studies, 96 as a primary outcome
- Stopped early22 studies, 12 as a primary outcome
- Status unknown88 studies, 58 as a primary outcome
What they test
- Behavioral72 studies, 46 as a primary outcome
- Drug67 studies, 45 as a primary outcome
- Device44 studies, 33 as a primary outcome
- Dietary supplement43 studies, 32 as a primary outcome
- Procedure12 studies, 9 as a primary outcome
- Diagnostic test17 studies, 7 as a primary outcome
- Biological6 studies, 2 as a primary outcome
- Radiation3 studies, 2 as a primary outcome
- Combination product1 studies, 1 as a primary outcome
- Other102 studies, 61 as a primary outcome
- None given24 studies, 14 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States91 studies, 62 as a primary outcome
- China43 studies, 32 as a primary outcome
- Canada20 studies, 13 as a primary outcome
- France20 studies, 7 as a primary outcome
- Spain19 studies, 14 as a primary outcome
- Italy16 studies, 12 as a primary outcome
- Taiwan14 studies, 5 as a primary outcome
- United Kingdom13 studies, 6 as a primary outcome
- Egypt10 studies, 8 as a primary outcome
- South Korea10 studies, 7 as a primary outcome
- Germany7 studies, 2 as a primary outcome
- Israel7 studies, 6 as a primary outcome
43 countries in all. A study with sites in several counts in each; 22 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed cognitive impairment and decline studies: 68 of 152, 45%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed cognitive impairment and decline studies | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 12, 8% | 776, 10% |
| Results on ClinicalTrials.gov only | 31, 20% | 1,139, 14% |
| A results paper only | 25, 16% | 1,711, 22% |
| Neither | 84, 55% | 4,327, 54% |
How many participants they enroll
- Phase 240 median, 14 to 65
- Phase 480 median, 48 to 102
- Not applicable60 median, 35 to 126
- Observational122 median, 63 to 243
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Phase 2 | 15 | 40 | 14 to 65 |
| Phase 4 | 19 | 80 | 48 to 102 |
| Not applicable | 214 | 60 | 35 to 126 |
| Observational | 72 | 122 | 63 to 243 |
When the cognitive outcome is measured
Latest time point of each outcome
- Within a day120 outcomes, 58 as a primary outcome
- Up to 4 weeks59 outcomes, 38 as a primary outcome
- 1 to 3 months162 outcomes, 108 as a primary outcome
- 3 to 6 months143 outcomes, 51 as a primary outcome
- 6 to 12 months92 outcomes, 37 as a primary outcome
- 1 to 2 years70 outcomes, 46 as a primary outcome
- Over 2 years27 outcomes, 10 as a primary outcome
- No duration given30 outcomes, 16 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
673 of the 703 outcome measures give a duration. A single visit counts as within a day.
Median time to the primary outcome, by test
| Test | Primary outcomes | Median |
|---|---|---|
| Verbal Learning | 41 | 13 weeks |
| Verbal Fluency | 34 | 13 weeks |
| Trail Making Test | 32 | 13 weeks |
| Digit Span Test | 28 | 12 weeks |
| Stroop Color-Word Test | 23 | 12 weeks |
| Symbol Coding | 17 | 13 weeks |
| Picture Naming Test | 15 | 6 months |
| Category Fluency | 11 | 6 months |
| N-Back Task | 10 | 2 weeks |
Explore the cognitive impairment and decline studies
262 studies match. 162 name a library test in a primary outcome. Median size 65 participants. Median time to the primary outcome: 13 weeks.
Loading 262 studies; the filters turn on when they arrive.
2026 is partly planned starts. Not shown: 1 planned to start after 2026 and 1 with no start year.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 2 | 1 |
| 2008 | 2 | 2 |
| 2009 | 2 | 2 |
| 2010 | 4 | 3 |
| 2011 | 4 | 1 |
| 2012 | 7 | 6 |
| 2013 | 8 | 7 |
| 2014 | 8 | 4 |
| 2015 | 10 | 7 |
| 2016 | 13 | 9 |
| 2017 | 23 | 11 |
| 2018 | 17 | 11 |
| 2019 | 22 | 12 |
| 2020 | 12 | 7 |
| 2021 | 17 | 11 |
| 2022 | 19 | 12 |
| 2023 | 27 | 17 |
| 2024 | 21 | 15 |
| 2025 | 24 | 12 |
| 2026 | 16 | 9 |
Library tests named most
Conditions
Phases
Participants
Lead sponsor: industry 24, other 238. Interventional 219, observational 43.
As a primary outcomeSecondary or other outcome
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07895979 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants216 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07891650 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants160 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07872189 | Start2027 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants136 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07833644 | Start2023 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants36 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07802392 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants230 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07766642 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants35 | Lead sponsorIndustry | StatusActive, not recruiting | Library tests named
|
| NCT07753382 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants36 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07751510 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants75 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07668440 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants71 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07584408 | Start2019 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants15 | Lead sponsorOther | StatusStopped early | Library tests named
|
| NCT07564804 | Start2025 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants60 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
| NCT07547319 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants80 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07531888 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants20 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07463391 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07453537 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants84 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07448675 | Start2023 | PhaseObservational | ConditionsCognitive impairment and decline | Participants230 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07412977 | Start2026 | PhaseObservational | ConditionsCognitive impairment and decline | Participants5,160 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07402161 | Start2025 | PhaseObservational | ConditionsCognitive impairment and decline | Participants250 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07377500 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants356 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07342075 | Start2025 | PhaseObservational | ConditionsCognitive impairment and decline | Participants50 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07334912 | Start2025 | PhasePhase 2 | ConditionsCognitive impairment and decline | Participants188 | Lead sponsorIndustry | StatusRecruiting | Library tests named
|
| NCT07334366 | Start2025 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants100 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07272174 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants50 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07242495 | Start2024 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants34 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07198399 | Start2025 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants35 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
Questions, answered from the data
Which cognitive test do cognitive impairment and decline trials use most?
Verbal Learning: 79 of the 354 registered studies name it in an outcome measure, 22%. Next come the Trail Making Test (77) and Verbal Fluency (63).
Which cognitive test do cognitive impairment and decline trials use most as a primary outcome?
Verbal Learning, named in a primary outcome by 43 studies. 230 of the 354 studies, 65%, name a cognitive test in a primary outcome.
How many participants does a phase 2 cognitive impairment and decline trial enroll?
Half of the phase 2 cognitive impairment and decline studies enroll 40 participants or fewer, and the middle half enroll 14 to 65. 15 of them give a size.
How long after the start do cognitive impairment and decline trials measure a cognitive outcome?
Half of the primary outcomes that name a library test are measured within 13 weeks of the start, and the middle half from 4 weeks to 11 months. 348 primary outcomes give a duration.
Which cognitive tests do cognitive impairment and decline trials use together?
The Trail Making Test with Verbal Learning most often: 34 studies name both. Next, the Trail Making Test with Verbal Fluency (29).
How many completed cognitive impairment and decline trials have reported results?
68 of the 152 completed cognitive impairment and decline studies, 45%, have reported results: 43 posted them on ClinicalTrials.gov, 37 have a results paper linked to the registry record, and 12 did both. The other 84 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
Plan the cognitive outcomes of a cognitive impairment and decline trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.